Zweig DiMenna Associates LLC Increases Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Zweig DiMenna Associates LLC lifted its position in BioLife Solutions, Inc. (NASDAQ:BLFSGet Rating) by 18.8% in the first quarter, HoldingsChannel.com reports. The firm owned 376,550 shares of the medical equipment provider’s stock after purchasing an additional 59,567 shares during the quarter. Zweig DiMenna Associates LLC’s holdings in BioLife Solutions were worth $8,559,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Russell Investments Group Ltd. increased its stake in shares of BioLife Solutions by 26.5% in the fourth quarter. Russell Investments Group Ltd. now owns 512,871 shares of the medical equipment provider’s stock worth $19,113,000 after purchasing an additional 107,584 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in shares of BioLife Solutions by 25.3% in the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 272,449 shares of the medical equipment provider’s stock worth $10,154,000 after acquiring an additional 55,000 shares during the last quarter. Nuveen Asset Management LLC lifted its holdings in shares of BioLife Solutions by 25.8% in the 4th quarter. Nuveen Asset Management LLC now owns 377,764 shares of the medical equipment provider’s stock worth $14,079,000 after acquiring an additional 77,364 shares during the last quarter. Ranger Investment Management L.P. increased its stake in BioLife Solutions by 43.0% in the 4th quarter. Ranger Investment Management L.P. now owns 1,255,260 shares of the medical equipment provider’s stock worth $46,784,000 after buying an additional 377,358 shares during the period. Finally, Marshall Wace LLP increased its position in BioLife Solutions by 4.2% during the 4th quarter. Marshall Wace LLP now owns 1,346,746 shares of the medical equipment provider’s stock valued at $50,193,000 after purchasing an additional 54,502 shares during the period. 83.48% of the stock is owned by hedge funds and other institutional investors.

A number of research analysts have recently issued reports on the stock. Oppenheimer raised shares of BioLife Solutions from a “market perform” rating to an “outperform” rating in a research report on Monday, April 25th. B. Riley cut their target price on shares of BioLife Solutions from $48.00 to $34.00 in a report on Tuesday, May 17th. StockNews.com raised shares of BioLife Solutions to a “sell” rating in a report on Friday, March 25th. Cowen lowered their price target on shares of BioLife Solutions from $50.00 to $32.00 in a research report on Tuesday, May 10th. Finally, Maxim Group lowered their price target on shares of BioLife Solutions from $60.00 to $30.00 in a research report on Thursday, May 12th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat, BioLife Solutions currently has a consensus rating of “Moderate Buy” and an average target price of $42.17.

In other BioLife Solutions news, COO Greef Roderick De sold 10,713 shares of BioLife Solutions stock in a transaction dated Thursday, April 7th. The stock was sold at an average price of $21.82, for a total value of $233,757.66. Following the completion of the sale, the chief operating officer now owns 104,464 shares in the company, valued at approximately $2,279,404.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael Rice sold 24,400 shares of BioLife Solutions stock in a transaction dated Monday, April 18th. The shares were sold at an average price of $17.59, for a total value of $429,196.00. Following the completion of the sale, the chief executive officer now owns 360,491 shares of the company’s stock, valued at approximately $6,341,036.69. The disclosure for this sale can be found here. In the last quarter, insiders have sold 129,097 shares of company stock valued at $2,332,296. 5.90% of the stock is currently owned by company insiders.

Shares of BLFS stock traded up $0.60 during mid-day trading on Tuesday, reaching $15.24. The stock had a trading volume of 2,055 shares, compared to its average volume of 511,702. BioLife Solutions, Inc. has a 12-month low of $10.40 and a 12-month high of $60.67. The business has a 50-day simple moving average of $13.40 and a 200 day simple moving average of $21.73. The company has a current ratio of 3.39, a quick ratio of 2.53 and a debt-to-equity ratio of 0.01.

BioLife Solutions (NASDAQ:BLFSGet Rating) last announced its quarterly earnings results on Monday, May 9th. The medical equipment provider reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The firm had revenue of $36.22 million during the quarter, compared to analysts’ expectations of $37.87 million. BioLife Solutions had a negative net margin of 10.35% and a negative return on equity of 6.24%. During the same quarter in the prior year, the business earned $0.01 EPS. On average, analysts forecast that BioLife Solutions, Inc. will post -0.39 earnings per share for the current fiscal year.

BioLife Solutions Profile (Get Rating)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Read More

Want to see what other hedge funds are holding BLFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioLife Solutions, Inc. (NASDAQ:BLFSGet Rating).

Institutional Ownership by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.